Literature DB >> 1764162

Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines.

I Facchetti1, M Grandi, P Cucchi, C Geroni, S Penco, A Vigevani.   

Abstract

Quantitative structure-activity relationship studies aimed at improving drug activity profiles require the determination of the physicochemical properties possibly involved in biological action. The lipophilic character of selected anthracyclines has been measured by means of reverse-phase high performance liquid chromatography, selecting appropriate experimental conditions. The capacity coefficients at zero percentage of the organic phase (log K0), which are retention indexes, have been used as lipophilicity descriptors in a QSAR study, involving as biological data the cytotoxicity of anthracyclines in a doxorubicin-sensitive (LoVo) and in a doxorubicin-resistant (LoVo/Dx) human cell lines. The results obtained in these in vitro models indicate that lipophilicity plays a role in anthracycline activity, influencing drug availability at the site of action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764162

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  3 in total

1.  Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Authors:  M Ripamonti; L Capolongo; G Melegaro; C Gornati; A Bargiotti; M Caruso; M Grandi; A Suarato
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.

Authors:  M Mariani; L Capolongo; A Suarato; A Bargiotti; N Mongelli; M Grandi; W T Beck
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

Authors:  M Ripamonti; G Pezzoni; E Pesenti; A Pastori; M Farao; A Bargiotti; A Suarato; F Spreafico; M Grandi
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.